-
TAS0728
- names:
TAS0728
- CAS号:
2088323-16-2
MDL Number: - MF(分子式): C26H32N8O3 MW(分子量): 504.58
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM004690-10mg | 10mg | 99.53% | ¥ 7425.00 | ¥ 7425.00 | 2-3天 | ¥ 0.00 | ||
| YZM009447-5mg | 5mg | 99.53% | ¥ 4515.00 | ¥ 4515.00 | In-stock | ¥ 0.00 | ||
| YZM004690-5mg | 5mg | 99.53% | ¥ 4550.00 | ¥ 4550.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | TAS0728 |
| CAS号 | 2088323-16-2 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C26H32N8O3 |
| 分子量 Molecular Weight | 504.58 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度125 mg/mL(247.73 mM;Need ultrasonic) |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
| 产品说明 | |
| Introduction | TAS0728 is a potent, selective, oral active, irreversible and covalent-bindingHER2inhibitor, binds to HER2 at C805, inhibits its kinase activity, with anIC50of 13 nM. TAS0728 showsIC50s of 4.9, 8.5, 31, 65, 33, 25, 86 and 36 nM for BMX, HER4, BLK, EGFR, JAK3, SLK, LOK and human HER2, respectively. TAS0728 also inhibits the phosphorylation of HER2, HER3, and downstream effectors, shows no obvious effect on EGFR. Antitumor activity[1]. |
| Application1 | |
| Application2 | |
| Application3 |
TAS0728 是一种有效的、选择性、可口服、不可逆、共价结合的HER2抑制剂,与HER2的 C805 位点共价结合,抑制其活性,IC50值为 13 nM。TAS0728 对 BMX,HER4,BLK,EGFR,JAK3,SLK,LOK 和 人 HER2 的IC50值分别为 4.9,8.5,31,65,33,25,86 和 36 nM。TAS0728 同时可抑制 HER2,HER3 及其下游效应蛋白的磷酸化。具有抗肿瘤活性。TAS0728 is a potent, selective, oral active, irreversible and covalent-bindingHER2inhibitor, binds to HER2 at C805, inhibits its kinase activity, with anIC50of 13 nM. TAS0728 showsIC50s of 4.9, 8.5, 31, 65, 33, 25, 86 and 36 nM for BMX, HER4, BLK, EGFR, JAK3, SLK, LOK and human HER2, respectively. TAS0728 also inhibits the phosphorylation of HER2, HER3, and downstream effectors, shows no obvious effect on EGFR. Antitumor activity[1].
| 【1】.Irie H, et al. TAS0728, a covalent-binding, HER2-selective kinase inhibitor shows potent antitumor activity in preclinical models. Mol Cancer Ther. 2019 Feb 20. |
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


